CytRx cites positive response to stroke therapy

Shares of CytRx were boosted after the company announced new data suggesting that its lead stroke therapy improved sensory and motor functions in animals. The preclinical study injected rats induced to have a stroke with the drug arimoclomol. Researchers found that even 48 hours after a stroke, the animals still responded positively to the therapy. CytRx now plans to launch a clinical trial to study the effects of the drug on humans. Arimoclomol is now in mid-stage trials for Lou Gehrig's disease.

- see the press release on the data
- here's the AP report

Related Articles:
CytRx forms new RNAi subsidiary. Report
CytRx wins fast track. Report
CytRx spins off RNAi assets into new company. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.